Advicenne S.A. (EPA:ALDVI)

Market Cap	22.24M
Revenue (ttm)	5.90M
Net Income (ttm)	-6.21M
Shares Out	14.17M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,929
Average Volume	18,259
Open	1.572
Previous Close	1.570
Day's Range	1.572 - 1.586
52-Week Range	1.104 - 2.200
Beta	0.91
RSI	43.21
Earnings Date	Dec 19, 2025

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2024, Advicenne's revenue was 5.27 million, a decrease of -0.51% compared to the previous year's 5.30 million. Losses were -6.46 million, -14.13% less than in 2023.